An interview discussing recent research on the association between GLP-1 receptor agonist use and the risk of atrial fibrillation.

NIH researchers have identified the intracellular signalling pathways through which semaglutide and other GLP-1 receptor agonists induce weight loss, revealing why patient responses vary and treatment ...

My brother-in-law is a lovely man, but for years, he's suffered from obesity. He also gambles and drinks alcohol too much. I ...

AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (T2DM) have become two of the most pressing healthcare challenges worldwide, driving ...

A team of researchers at the National Institutes of Health (NIH) have unveiled new details about the events GLP-1 receptor agonists trigger within neurons, which have been largely unexplored until now ...

GLP-1 receptor agonists, already used for Type 2 diabetes and obesity, show promise in reducing alcohol and drug-seeking ...

GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week at the American Society of Clinical Oncology’s annual meeting.

GLP-1 receptor agonists may confer neuroprotection via reduced neuroinflammation, inhibited apoptosis, and vasodilatory effects that enhance cerebral perfusion through cAMP and VEGF-related pathways.

The use of GLP-1 RAs may be appropriate among select patients with psoriasis, although additional research is needed to guide ...

GLP-1s were linked to a lower death risk in colon cancer in a recent study. Image credit: ARMEND NIMANI/Getty Images “This means that, “in addition to lowering glucose [blood sugar] and weight, they ...

Resolution occurred after stopping dulaglutide, no obvious clues to mechanism ...